ReviewJournal of molecular medicine (Berlin, Germany)2004
Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers.
Review in Journal of molecular medicine (Berlin, Germany), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- CMGC Kinases in Viral Infection and Human Disease.Pathogens (Basel, Switzerland) · 2026Review
- Epigenetics of Cutaneous Sarcoma.International journal of molecular sciences · 2021Review
- Regulation of Wnt/β-catenin signaling by herpesviruses.World journal of virology · 2016Review
- KSHV Genome Replication and Maintenance.Frontiers in microbiology · 2016Review
- A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.Journal of virology · 2015Article
- Beta-catenin and epithelial tumors: a study based on 374 oropharyngeal cancers.BioMed research international · 2014Article
- A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-κB.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Human herpesvirus 8 interferon regulatory factor-mediated BH3-only protein inhibition via Bid BH3-B mimicry.PLoS pathogens · 2012Article
- The latency-associated nuclear antigen, a multifunctional protein central to Kaposi's sarcoma-associated herpesvirus latency.Future microbiology · 2011Review
- Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.Cancer letters · 2011Review
- Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis.Advances in virus research · 2010Review
- Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders.Journal of clinical pathology · 2007Review
- Gamma-herpesviruses and cellular signaling in AIDS-associated malignancies.Cancer science · 2007Review
- Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA.Virology · 2007Article
- Structure and function of latency-associated nuclear antigen.Current topics in microbiology and immunology · 2007Review
- Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells.Journal of virology · 2004Article
- Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.Neurochemical researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Kaposi's sarcoma-associated herpesvirus, KSHV, is associated with cancers that have increased incidence in patients who are also HIV positive or who have undergone organ transplantation. It has recently been observed that beta-catenin is overexpressed in two KSHV-associated cancers, Kaposi's sarcoma and primary effusion lymphoma. Investigation of the underlying defect in beta-catenin regulation revealed that the KSHV-encoded LANA protein stabilizes beta-catenin by binding to the negative regulator GSK-3, causing a cell-cycle-dependent nuclear accumulation of GSK-3. Thus, redistribution of GSK-3 has been identified as yet another mechanism through which beta-catenin can be dysregulated and contribute to human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.